AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.

By MarketWatch | Nov 11, 2024 at 10:47 AM EST

AbbVie's stock dropped significantly as their schizophrenia drug, emraclidine, failed to show significant improvement in two Phase 2 trials. The drug did not meet the primary endpoint of demonstrating a statistically significant reduction in symptoms compared to the placebo group.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.